PO.CL01.14 · 临床研究
肿瘤学研究中的嵌合抗体:特性及其在低重(low-multiplexing)检测中的应用
Chimeric antibodies in oncology research: Properties and application in low-multiplexing assays
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
嵌合抗体是通过将一个物种(如兔)的可变(抗原结合)结构域与另一个物种(如人、鸡)的恒定结构域融合而构建的,代表了抗体技术的一项重大进步。该方法在保留原始抗体的特异性和亲和力的同时,引入了来自第二个物种的理想特性。除治疗用途外,嵌合抗体的独特特性在体外诊断和研究应用中亦具有显著优势,例如在低重(low-multiplexing)检测中。特别是,嵌合抗体在多重检测中具有显著优势,其物种特异性的恒定区允许在交叉反应性极小的情况下同时使用多种一抗。嵌合抗体的使用与多种实验设置兼容,使研究人员能够利用现有的二抗系统。在此,我们展示了使用嵌合抗体构建免疫组织化学(IHC)panel的优势,用于共同检测福尔马林固定石蜡包埋(FFPE)人肿瘤组织中的癌症蛋白标志物,并研究其组织微环境(TME)。通过利用来源于多个宿主物种(包括小鼠、兔和鸡)的抗体,我们在正常样本和肿瘤样本中均实现了稳健且特异的染色。我们的结果凸显了嵌合抗体在简化复杂IHC工作流程、以及提高癌症研究中多重组织分析分辨率方面的潜力。
查看英文原文 English abstract
Chimeric antibodies, engineered by fusing the variable (antigen-binding) domains of one species (e.g. rabbit) with the constant domains of a different species (e.g. human, chicken), represent a significant advancement in antibody technology. This approach preserves the original antibody's specificity and affinity while introducing desirable features from the second species. Beyond therapeutics, the distinctive characteristics of chimeric antibodies offer notable benefits in in vitro diagnostic and research applications, for example in low-multiplexing assays. In particular, chimeric antibodies offer significant advantages in multiplexed assays, where their species-specific constant regions allow for the simultaneous use of multiple primary antibodies with minimal cross-reactivity. The use of chimeric antibodies is compatible with diverse experimental setups allowing researchers to leverage existing secondary antibodies systems. Here we demonstrate the advantage of using chimeric antibodies for building immunohistochemistry (IHC) panels for the co-detection of cancer protein markers and the study of tissue micro environment (TME) in formalin-fixed paraffin-embedded (FFPE) human tumor tissues. By leveraging antibodies derived from multiple host species, including mouse, rabbit, and chicken, we achieved robust and specific staining in both normal and tumor samples. Our results highlight the potential of chimeric antibodies to streamline complex IHC workflows and improve the resolution of multiplexed tissue analyses in cancer research.
利益披露 Disclosure
T. Bright,
Abcam Ltd Employment.
N. Nelson,
Abcam Ltd Employment.
A. Galli,
Abcam Ltd Employment.
W. Howat,
Abcam Ltd Employment.
S. Sbacchi,
Abcam Limited Employment.